Janssen and Johnson & Johnson to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients with Type 2 Diabetes

NEW BRUNSWICK, N.J., Sept. 26, 2012 /PRNewswire-FirstCall/ -- Janssen Research & Development, LLC and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Tuesday, October 2, at approximately 12:00 p.m., Eastern Time, to coincide with the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, Germany.

First results from the ongoing phase 3 CANVAS trial evaluating canagliflozin in patients with type 2 diabetes at elevated risk for cardiovascular disease will be shown at EASD.  Additionally, data from DIA3010, which evaluated canagliflozin as add-on therapy in patients aged 55 to 80, on antihyperglycemic therapy without adequate glycemic control, will be presented.

A pre-recorded webcast with Kirk Ways, M.D., Ph.D, Vice President and compound development team leader for canagliflozin from Janssen Research & Development, will provide an update on the CANVAS sub-study and DIA3010 results.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."

SOURCE Johnson & Johnson

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

Bluebird has priced gene therapy Zynteglo at €1.575 million in Europe and promised a U.S. price in “reasonably close” range.

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.